Please fill out the form to subscribe now

Categorized in News

September 23, 2021

Sona Updates on Strategy and Test Development Progress

Sona leverages on its core GNR manufacturing technology, scientific experience, and laboratory asset to focus on two strategic priorities for its business: the development of rapid diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property towards important medical in vivo applications. 

Read more

June 15, 2021

Sona Discontinues Clinical Trial for COVID-19 Rapid Saliva Test

The study was designed to evaluate the ability to detect the COVID-19 virus in saliva samples using a novel collection device and a rapid antigen test cassette.  The Company plans to focus its research strategy on continuing with its other rapid test development programs and research on its proprietary gold nanorod production technology. 

Read more

April 22, 2021

Sona to Commence Clinical Trial for COVID-19 Rapid Saliva Test

As previously announced in the Company’s news release dated April 12, 2021, the trial will occur in partnership with the Humber River Hospital in Toronto, with the objective to determine the clinical performance of the test when compared to RT-PCR, in symptomatic patients.

Read more

April 13, 2021

Sona Secures Clinical Trial Authorization and Hospital Partner

David Regan, CEO, comments "New, less invasive rapid tests are needed to support frequent testing and a test that works with saliva would make regular testing for everyone much more accessible and tolerable. Developing a rapid antigen test for COVID-19 that works with saliva is complex...

Read more

March 23, 2021

Sona Announces Filing of Preliminary Short Form Base Shelf Prospectus

The Shelf Prospectus, when made final, will enable the Company to offer up to $20,000,000 of common shares, debt securities, warrants, subscription receipts and units (collectively, the “Securities”), or any combination of such Securities from time to time, during the 25-month period that the Shelf Prospectus is effective.

Read more